Joseph W Franses
Overview
Explore the profile of Joseph W Franses including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Taylor M, Connie W, Fridy P, Zhang S, Senussi Y, Wolters J, et al.
bioRxiv
. 2023 Feb;
PMID: 36747644
Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. While proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for...
12.
Lim M, Franses J, Imperial R, Majeed U, Tsai J, Hsiehchen D
Gastroenterology
. 2023 Jan;
164(6):1006-1008.e3.
PMID: 36708791
No abstract available.
13.
Franses J, Lim M, Burgoyne A, Mody K, Lennerz J, Chang J, et al.
Oncologist
. 2022 Sep;
27(11):e908-e911.
PMID: 36103364
Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA)...
14.
Franses J, Bhan I, Zhu A
Med
. 2022 May;
2(7):788-790.
PMID: 35590215
Cirrhosis confers a variable risk of developing hepatocellular carcinoma (HCC), but the risk varies significantly depending upon ill-defined factors. In this issue of Med, Fujiwara et al. use hepatic gene...
15.
Franses J, Zhu A
Clin Cancer Res
. 2022 Mar;
28(13):2738-2743.
PMID: 35266995
Hepatocellular carcinoma (HCC) remains a lethal malignancy and is an increasingly common cause of cancer death worldwide. Curative-intent surgical resection remains the standard of care for eligible patients, yet outcomes...
16.
Furtado F, Wu M, Esfahani S, Ferrone C, Blaszkowsky L, Clark J, et al.
Ann Surg
. 2022 Feb;
277(4):e893-e899.
PMID: 35185121
Objective: To compare positron emission tomography (PET)/magnetic resonance imaging (MRI) to the standard of care imaging (SCI) for the diagnosis of peritoneal carcinomatosis (PC) in primary abdominopelvic malignancies. Summary Background...
17.
Missios P, Lummertz da Rocha E, Pearson D, Philipp J, Aleman M, Pirouz M, et al.
J Clin Invest
. 2021 Nov;
131(22).
PMID: 34779407
High expression of LIN28B is associated with aggressive malignancy and poor survival. Here, probing MYCN-amplified neuroblastoma as a model system, we showed that LIN28B expression was associated with enhanced cell...
18.
Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden
Franses J, Bhan I, Pankaj A, Ting D, Deshpande V, Tanabe K
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34585041
No abstract available.
19.
Parikh A, Van Seventer E, Siravegna G, Hartwig A, Jaimovich A, He Y, et al.
Clin Cancer Res
. 2021 Apr;
27(20):5586-5594.
PMID: 33926918
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing...
20.
Van Seventer E, Fish M, Fosbenner K, Kanter K, Mojtahed A, Allen J, et al.
Cancer
. 2020 Nov;
127(4):619-627.
PMID: 33170962
Background: Patient-reported outcomes (PROs) assessing quality of life (QOL) and symptom burden correlate with clinical outcomes in patients with cancer. However, to the authors' knowledge, data regarding associations between PROs...